From Bench to Bedside: Novel Molecular Targets and Therapeutic Strategies in AML
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 May 2026 | Viewed by 260
Special Issue Editor
Interests: acute myeloid leukemia; chronic myeloid leukemia; myelodisplastic syndromes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy with historically poor outcomes, especially in older or unfit patients. The advent of targeted therapies—such as FLT3, IDH1/2, BCL2, and menin inhibitors—has transformed the therapeutic landscape, enabling precision medicine approaches tailored to specific molecular alterations. These agents, often used in combination with hypomethylating agents or intensive chemotherapy, have shown the potential to improve remission rates, survival, and quality of life. Despite these advances, challenges remain regarding resistance mechanisms, optimal sequencing, and integration with allogeneic transplantation or immunotherapy. This Special Issue will gather cutting-edge original research and comprehensive reviews on novel targets, biomarkers, and strategies to optimize patient selection, with the ultimate goal of personalizing and improving AML treatment outcomes.
Dr. Matteo Molica
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- targeted therapy
- precision medicine
- FLT3 inhibitors
- IDH1/2 inhibitors
- BCL2 inhibition
- menin inhibitors
- drug resistance
- minimal residual disease
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
